Anchiano Therapeutics Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
- Financing Rounds
-
10
- Investments
-
1
Anchiano Therapeutics General Information
Description
Operator of a biopharmaceutical firm intended for the discovery, development and commercialization of novel targeted therapies to treat cancer. The company specializes in the treatment of various cancer cures such as non-muscle-invasive bladder, advanced malignant neoplasms, metastatic lung and metastatic liver treatments.
Contact Information
Website
www.anchiano.comCorporate Office
- One Kendall Square, Building 1400 East
- Suite 14-105
- Cambridge, MA 02139
- United States
Corporate Office
- One Kendall Square, Building 1400 East
- Suite 14-105
- Cambridge, MA 02139
- United States
Anchiano Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anchiano Therapeutics Comparisons
Industry
Financing
Details
Anchiano Therapeutics Competitors (3)
One of Anchiano Therapeutics’s 3 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Boehringer Ingelheim | Corporation | Ingelheim Am Rhein, Germany |
Anchiano Therapeutics Signals
Anchiano Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Anchiano Therapeutics Acquisitions (1)
Anchiano Therapeutics’s most recent deal was a Reverse Merger with Chemomab Therapeutics for . The deal was made on 16-Mar-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Chemomab Therapeutics | 16-Mar-2021 | Reverse Merger | Drug Discovery |
Anchiano Therapeutics Exits (1)
Anchiano Therapeutics’s most recent exit was on 16-Mar-2021 from Chemomab Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Chemomab Therapeutics | 16-Mar-2021 | Completed |
|
Anchiano Therapeutics FAQs
-
When was Anchiano Therapeutics founded?
Anchiano Therapeutics was founded in 2004.
-
Where is Anchiano Therapeutics headquartered?
Anchiano Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Anchiano Therapeutics?
Anchiano Therapeutics has 3 total employees.
-
What industry is Anchiano Therapeutics in?
Anchiano Therapeutics’s primary industry is Drug Discovery.
-
Is Anchiano Therapeutics a private or public company?
Anchiano Therapeutics is a Private company.
-
What is Anchiano Therapeutics’s current revenue?
The current revenue for Anchiano Therapeutics is .
-
How much funding has Anchiano Therapeutics raised over time?
Anchiano Therapeutics has raised $61.8M.
-
Who are Anchiano Therapeutics’s investors?
Arc Ventures (United States), Clal Biotechnology Industries, Hebrew University of Jerusalem Endowment, Palisade Capital Management, and Shavit Capital are 5 of 7 investors who have invested in Anchiano Therapeutics.
-
Who are Anchiano Therapeutics’s competitors?
Amgen, Merck & Co., and Boehringer Ingelheim are competitors of Anchiano Therapeutics.
-
When was Anchiano Therapeutics acquired?
Anchiano Therapeutics was acquired on 16-Mar-2021.
-
Who acquired Anchiano Therapeutics?
Anchiano Therapeutics was acquired by Chemomab Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process